XM does not provide services to residents of the United States of America.
U
U

UNIQA


News

Natural disasters could force insurer Uniqa to alter products, CEO says

Natural disasters could force insurer Uniqa to alter products, CEO says Sept 5 (Reuters) - Austria's second largest insurer Uniqa UNIQ.VI might have to stop insuring certain regions, CEO Andreas Brandstetter told Reuters on Thursday, as it faces rising pay outs thanks to extreme weather events. "We have to think carefully about which products we offer where and at what price", Brandstetter said without going into further detail.
U

Argenx, Glencore, Volvo Car

EUROPE RESEARCH ROUNDUP- Argenx, Glencore, Volvo Car Aug 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Argenx, Glencore and Volvo Car, on Friday. HIGHLIGHTS * Argenx SE ARGX.BR : JP Morgan raises target price to EUR 570 from EUR 470 * Glencore GLEN.L : Morgan Stanley cuts target price to 470p from 480p * Rockwool A/S ROCKb.CO : Morgan Stanley raises PT to DKK 3023 from DKK 2664 * Swiss Re AG SRENH.S : RBC raises target price t
B
G
H
K
S
S
S
U
E
S
S

UNIQA Insurance Says Payout Ratio Will Remain Unchanged At Up To 60 Per Cent

BRIEF-UNIQA Insurance Says Payout Ratio Will Remain Unchanged At Up To 60 Per Cent Aug 22 (Reuters) - UNIQA INSURANCE GROUP AG UNIQ.VI : OUTLOOK: IN CONNECTION WITH THIS, WE EXPECT OUR TARGET PROFITABILITY TO BE AT THE LEVEL OF 2023 PAYOUT RATIO WILL REMAIN UNCHANGED AT UP TO 60 PER CENT Further company coverage: UNIQ.VI (Gdansk Newsroom)
U

UBS points to 'attractive' market mix for Austrian insurers

BUZZ-UBS points to 'attractive' market mix for Austrian insurers ** UBS highlights Austrian insurers' "attractive combination" of exposure to a developed home market and the growing Central and Eastern European market ** It starts coverage of Vienna Insurance VIGR.VI and UNIQA UNIQ.VI with respectively "buy" and "neutral" ratings ** Owing to th e e
U

AstraZeneca, Beazley, Puma

EUROPE RESEARCH ROUNDUP-AstraZeneca, Beazley, Puma Aug 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Beazley and Puma on Monday. HIGHLIGHTS * AstraZeneca AZN.L : TD Cowen raises target price to 14,860p from 13,945p * Beazley BEZG.L : Jefferies raises target price to 1,020p from 975p * Puma SE PUMG.DE : Baader Helvea raises to buy from add * Quilter Plc QLT.L : Berenberg raises target price to 135p from 105p * WPP
A
B
B
B
D
D
E
H
J
J
L
L
M
M
O
P
S
S
U
V
W
A
A
B
B
R



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.